DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure by Kettunen, E et al.
DNA copy number loss and allelic imbalance at 2p16 in lung
cancer associated with asbestos exposure
E Kettunen*,1, M Aavikko
1, P Nymark
1,2, S Ruosaari
1,3, H Wikman
4, E Vanhala
5, K Salmenkivi
2, R Pirinen
6,
A Karjalainen
7, E Kuosma
7 and S Anttila
1,2
1Health and Work Ability, Finnish Institute of Occupational Health, Topeliuksenkatu 41 aA, 00250 Helsinki, Finland;
2Department of Pathology,
Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 3, 00140 Helsinki, Finland;
3Laboratory of Computer and Information Science, Helsinki Institute for Information Technology, Helsinki University of Technology, Konemiehentie2 ,
02015 Espoo, Finland;
4Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany;
5Work Environment Development, Finnish Institute of Occupational Health, Topeliuksenkatu 41 aA, 00250 Helsinki, Finland;
6Department of Pathology
and Forensic Medicine, Institute of Clinical Medicine, University of Kuopio and Kuopio University Hospital, P.O.BOX 1627, 70210 Kuopio, Finland;
7Good Practices and Competence, Finnish Institute of Occupational Health, Topeliuksenkatu 41 aA, 00250 Helsinki, Finland
Five to seven percent of lung tumours are estimated to occur because of occupational asbestos exposure. Using cDNA microarrays,
we have earlier detected asbestos exposure-related genomic regions in lung cancer. The region at 2p was one of those that differed
most between asbestos-exposed and non-exposed patients. Now, we evaluated genomic alterations at 2p22.1-p16.1 as a possible
marker for asbestos exposure. Lung tumours from 205 patients with pulmonary asbestos fibre counts from 0 to 570 million fibres per
gram of dry lung, were studied by fluorescence in situ hybridisation (FISH) for DNA copy number alterations (CNA). The prevalence
of loss at 2p16, shown by three different FISH probes, was significantly increased in lung tumours of asbestos-exposed patients
compared with non-exposed (P¼0.05). In addition, a low copy number loss at 2p16 associated significantly with high-level asbestos
exposure (P¼0.02). Furthermore, 27 of the tumours were studied for allelic imbalances (AI) at 2p22.1–p16.1 using 14 microsatellite
markers and also AI at 2p16 was related to asbestos exposure (P¼0.003). Our results suggest that alterations at 2p16 combined
with other markers could be useful in diagnosing asbestos-related lung cancer.
British Journal of Cancer (2009) 100, 1336–1342. doi:10.1038/sj.bjc.6605012 www.bjcancer.com
Published online 31 March 2009
& 2009 Cancer Research UK
Keywords: lung cancer; asbestos exposure; genetic marker; allelic imbalance
                                                      
Lung cancer is the leading cause of cancer-related deaths, causing
almost 1.2 million deaths per year worldwide (Parkin et al, 2005).
Several risk factors are known to contribute to the outbreak of lung
cancer, of which tobacco is by far the most predominant (Peto,
1994). However, exposures to occupational carcinogens, such as
asbestos, are also well-established causal factors of lung cancer.
Asbestos refers to a group of naturally occurring fibrous silicate
minerals, which have been widely exploited in, for example, the
building industry. Although banned in many countries, asbestos
exposure continues to be a serious risk factor for lung cancer,
because of the long latency period between initial exposure and
outbreak of the disease (Consensus report, 1997; Henderson et al,
2004). Five to seven percent of all lung cancer cases are estimated
to occur because of occupational asbestos exposure (LaDou, 2004).
So far, probability based on epidemiological studies of lung cancer
risk with a certain asbestos exposure level has been considered the
best way to estimate whether, in individual cases, a lung tumour
has been caused by the patient’s earlier exposure to asbestos.
Several mechanisms have been proposed to be involved in
asbestos-induced cytotoxicity and genotoxicity, the formation of
reactive species of oxygen or nitrogen being particularly central
(Xu et al, 1999; Unfried et al, 2002). Asbestos fibres have been
shown to induce damage at both DNA and chromosomal levels, as
well as abnormal chromosome segregation (Dopp and Schiffmann,
1998; Okayasu et al, 1999; Unfried et al, 2002). We were recently
able to identify specific gene copy number and expression profiles
in lung cancer of asbestos-exposed patients (Nymark et al, 2006;
Wikman et al, 2007). In the earlier studies, six chromosomal
regions were identified to be affected by both DNA copy number
alterations (CNA) and gene expression changes, and differed
between lung tumours of asbestos-exposed and non-exposed
patients. One of the identified regions was 2p21–p16.3 (Nymark
et al, 2006; Wikman et al, 2007). Furthermore, treatment with
crocidolite asbestos fibres in the lung cell lines, A549 and Beas-2B,
has been shown to result in altered gene expression at 2p22
(Nymark et al, 2007). Here we have further explored 2p22–2p16 by
fragment analysis for detecting allelic imbalance (AI) and to
localise the specific asbestos-targeted core region. Furthermore,
CNA was studied in a large number of lung tumours by
fluorescence in situ hybridisation (FISH). Particularly, we showed
that low copy number loss and AI at 2p16 in lung cancer were
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ssignificantly associated with patients’ past occupational exposure
to asbestos.
MATERIAL AND METHODS
Lung tumours and normal lung tissue
Lung tumour samples from 205 patients were used in this
study. The study population is presented in Table 1. Fresh-frozen
lung tumour samples (n¼81) have been obtained from patients
operated during 1990–1996 at the Department of Thoracic and
Cardiovascular Surgery of the Helsinki University Central
Hospital. The informed consents of these patients were obtained
and they have been personally interviewed for their work history.
The Ethical Review Board for Research in Occupational Health and
Safety, and the Coordinating Ethical Review Board, Helsinki and
Uusimaa Hospital District (75/E2/2001) have approved the study
protocol and the collection of fresh-frozen lung tumour samples
and personally interviewed data.
Formalin-fixed paraffin-embedded (FFPE) samples of lung
tumours (n¼124) were received from different Hospitals in
Finland. These patients’ pulmonary asbestos fibre counts had been
analysed at the Finnish Institute of Occupational Health as a part
of earlier exposure assessment. The National Agency for Medico-
legal Affairs (4476/33/300/05) permitted the use of tissue samples
originally obtained for histopathological diagnosis, and the
Ministry for Social Affairs and Health (STM/2474/2005) permitted
the collection of patient information for this study.
The pulmonary asbestos fibre counts of all the patients were
analysed by electron microscopy with energy dispersive spectro-
metry (Karjalainen et al, 1993). We considered a patient to be
asbestos-exposed if the fibre count was X1.0 million fibres per
gram of dry weight, which is usually considered as a sign of
occupational asbestos exposure and to be associated with
increased risk for lung cancer (Karjalainen et al, 1993, 1994).
The median fibre count among the exposed patients was 6.6
milliong
 1 (range 1.0–570 milliong
 1). Furthermore, asbestos-
exposed patients with fibre counts of X5 million fibres per gram
were considered as highly exposed. It has been reported that the
background level of asbestos in the general population may rise up
to 1.0 million fibres per gram (Miserocchi et al, 2008). To highlight
the contrast between the exposed and non-exposed, we considered
patients with fibre counts of p0.5 million fibres per gram to be
non-exposed. Specimens obtained from patients with a fibre count
between 0.5 and 1 million fibres per gram were not collected. In
addition, morphologically normal lung from 27 of the lung tumour
patients were studied for AI. The 27 patients included in the AI
study have been studied earlier by cDNA microarrays, and among
this group there were non-exposed patients and highly asbestos-
exposed patients with pulmonary fibre count X5.0 million fibres
per gram (Nymark et al, 2006).
Fluorescence in situ hybridisation
Bacterial artificial chromosomes (BAC) from the clones RP11-
1114A19, RP11-347F1, RP11-703K23, RP11-963J22, and RP11-
183P21 were used as FISH probes. The probes are shown in
Figure 1, together with the corresponding microsatellite markers.
The BAC clones were obtained from BACPAC Resources (CHORI,
Oakland, CA, USA). DNA was extracted using Qiagen plasmid midi
kit (Qiagen, Valencia, CA, USA) and labelled by nick-translation
with either biotin-14-dATP (Invitrogen Life Technologies,
Carlsbad, CA, USA) (Kettunen et al, 2000) or Spectrum Green
dUTP using a Nick Translation kit (Vysis Inc./Abbott Molecular
Inc., Downers Grove, IL, USA). For the centromere of chromosome
2, either a Spectrum Orange-labelled CEP2 DNA probe (alpha
satellite; Vysis, Inc./Abbott Molecular, Inc.) or a rhodamine-
labelled chromosome 2 satellite probe (Qbiogene, KREATECH
Biotechnology BV, Amsterdam, The Netherlands) was used. Both
are referred to as CEP2 in the following.
A total of 87% of the FFPE tumours were sampled and put onto
the tissue microarrays (TMA), and 13% of the FFPE tumours were
studied as biopsy section slides. Before fluorescence microscopic
analysis, serial sections of TMAs and biopsies were stained with
haematoxylin and eosin for identification of tumour cells. After
paraffin removal of TMA and biopsy section slides, and hydration
of fresh-frozen tissue slides, the samples were treated in 0.01 M
citrate, pH 6.0 at 801C for 2h (Chin et al, 2003). For digestion, we
Table 1 Summary of study population
Fluorescence in situ hybridization (FISH) Allelic imbalance (AI)
Formalin-fixed paraffin-embedded material Surgical fresh-frozen material Surgical fresh-frozen material
n¼124 n¼81 n¼27
a
Sex
Male/female 119/5 73/8 27/0
Age
Mean (range) 65 (42–87) 62 (36–81) 62 (41–72)
Histology of tumours and asbestos exposure status
AC exposed 23 16 5
AC non-exposed 14 18 6
SCC exposed 28 11 3
SCC non-exposed 19 17 4
SCLC exposed 11 1 1
SCLC non-exposed 9 4 1
LCLC exposed 7 4 3
LCLC non-exposed 3 3 2
Other LC exposed
b 71 1
Other LC non-exposed
c 36 1
Abbreviations: AC¼adenocarcinoma; LC¼lung cancer; LCLC¼large cell lung carcinoma; SCC¼squamous cell carcinoma; SCLC¼small cell lung cancer.
aSame tumours as
fresh-frozen material are included in the FISH study.
bTumours consisted of three pleomorphic, three large cell neuroendocrine carcinomas, one adenosquamous carcinoma, and
one undefined non-small cell lung cancer in FISH study, and one adenosquamous carcinoma in AI study.
cTumours consisted of one pleomorphic and four adenosquamous
carcinomas, one undefined non-small cell lung cancer, and three large cell neuroendocrine carcinomas, one combined with squamous cell cancer in FISH study, and one
adenosquamous carcinoma in AI study.
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sused DigestAll3 (Zymed Laboratories Invitrogen Immunodetec-
tion, San Francisco, CA, USA) at 371C for 10min. Denaturation,
dehydrations, and hybridisation were carried out as described
earlier (Kettunen et al, 2000; Andersen et al, 2001). Post-
hybridisation washes for directly labelled BAC probes and for
CEP2 were carried out according to manufacturer’s instructions.
Biotin-conjugated BAC probes were washed as described earlier
(Kettunen et al, 2000), using fluorescein–avidin D and bio-
tinylated anti-avidin D (Vector Laboratories Inc. Burlingame, CA,
USA) for visualisation. The slides were counterstained with
diamidino-2-phenylindole (DAPI) to identify tumour cells by
morphology in fluorescence microcopy.
All the BAC probes were hybridised on metaphase chromosomes
to ensure correct localisation at 2p (Figure 2A). FISH hybridisa-
tions were analysed using a Zeiss Axioplan fluorescence micro-
scope (Zeiss, Jena, Germany). To calculate the locus-specific copy
number changes in each case, we divided the copy numbers of each
probe by the mean count of centromere 2.
For each specimen, at least 100 cells were scored wherever
possible. Owing to the large number of overlapping cells, we were
able to count only 50–100 cells in 19% of the TMA specimens,
and 30–50 cells in 12% of the TMA specimens and in 35% of the
biopsy specimens. The mean signal count was calculated for each
specimen. The FISH slides were divided into two sets containing
specimens from both asbestos-exposed and non-exposed patients,
and were analysed by two persons independently. Tissue cores
with normal lung or lymph node material were used as negative
controls in the TMA slides. In addition, lymphocytes or other non-
cancerous cells showing two signals served as internal controls in
each specimen.
To obtain locus-specific CNA at 2p in each case, we calculated
the ratio between the mean signal count of each BAC probe and the
mean signal count of CEP2. It has been reported that approxi-
mately half of all lung tumours are polyploid (Mitelman et al,
2009). In a case, in which the genome of the tumour cells is
triploid, the fourth copy of locus DNA would show as a 33%
increase in DNA copy number compared with the mean of
centromeres. Thus, to be able to detect low CNA, we used the
thresholds X1.3 for gain and p0.75 for loss of DNA.
Fragment analyses for detection of allelic imbalances
DNA from snap-frozen normal lung tissue was extracted using
QIAamp Tissue Kit (Qiagen). Sections (4mm) from snap-frozen
lung tumour tissue specimens were stained with 1% toluidine
blue–0.2% methylene blue solution for 20s and dehydrated. The
laser capturing procedure was carried out using Arcturus Veritas
microdissecting device (Arcturus, Mountain View, CA, USA).
Tumour cells were captured in CapSure Macro LCM caps
(Arcturus, Mountain View, CA, USA) and DNA was extracted
using Pico Pure DNA extraction kit (Arcturus).
Fragment analysis was carried out at 2p22–p16.1 (16.6Mbp) using
14 microsatellite markers (Figure 1) to detect AI. Primers were
labelled with FAM, HEX, or NED fluorochrome (TIB MOLBIOL
Syntheselabor GmbH, Berlin, Germany or Applied Biosystems,
Warrington, Cheshire, UK). The target sequences were amplified in
tumour and corresponding normal lung tissue. PCR products of
different sizes and fluorochromes were further combined and run
with electrophoresis using 3100 Avant Genetic Analyzer (Applied
Biosystems). The results were analysed with GeneMapper Analysis
2p12
2p24
2p25
D2S378 57157077
D2S2153 54561970 RP11-1114A19 54554031–54680411
D2S2251 54063274
D2S123 51141882 RP11-347F1 51048050–51215674
D2S2739 49475655 RP11-703K23 49328415–49513864
D2S288 46398565
D2S391 46264872 RP11-963J22 46254649–46417680
D2S2182 46119126
D2S2378 46112137 RP11-183P21 46081709–46175720
D2S2240 45897520
D2S2174 45032148
D2S2298 43995783
D2S119 43927487
D2S2259 42850051
D2S2328 40532153
2p11(CEN)
Microsatellite 
marker:
Microsatellite 
marker start bp:
BAC start-end bp: BAC clone:
2p22.1
2p16.2
2p16.1
2p16.3
2p21
Figure 1 P arm of chromosome 2 showing microsatellite markers and bacterial artificial chromosome (BAC) clones used in fragment analyses and in
fluorescent in situ hybridisation. Start and end base pairs are presented according to the University of California Santa Cruz (UCSC) genome browser.
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sSoftware version 3.5 (Applied Biosystems). Allelic ratios were
calculated between the two highest peaks with the expected fragment
length for heterozygous markers in both tumour and normal DNA.
Allelic imbalances were suggested when the ratio of the allelic ratios
between the tumour and normal DNA was 2.0 or higher.
RESULTS
Copy number alterations
Using FISH, we obtained the DNA copy numbers at 2p21–p16 in
55–156 lung tumours, depending on the probe and at centromere
of chromosome 2 (alpha satellite) in 181 lung tumours. Locus-
specific CNA was obtainable in 54–134 cases, depending on the
BAC probe. The CEP2 signal count in lung tumour cells was on
average 2.7 (range 1.6–5.7), varying between the lung tumour
types as follows: adenocarcinoma of the lung (AC): 2.7; squamous
cell carcinoma of the lung (SCC): 2.6; large cell lung cancer (LCLC):
3.0; and small cell lung cancer (SCLC): 2.6. Among the asbestos-
exposed and non-exposed cases, the CEP2 mean signal counts were
2.7 (range 1.6–5.4) and 2.6 (range 1.6–5.7), respectively.
Locus-specific CNA results are shown in Table 2a. Both gains
and losses of DNA were found (Figure 2B and C). In gains, the
signals were evenly spread in the nuclei (Figure 2B).
The difference in DNA status between the exposed and non-
exposed patients’ lung tumours was tested at two stages. At first,
we compared the frequencies of cases with losses, gains, and no
CNA (Fisher’s exact test or w
2-test). If P was o0.10, we continued
by comparing the frequency of losses with the frequency of gains
as well as the frequency of losses with the frequency of no CNA
(Fisher’s exact test or w
2-test). The RP11-703K23 probe at 2p16.3
showed association with asbestos exposure (P¼0.09, Fisher’s exact
test) when comparing the difference between frequencies of losses,
gains, and no CNA. Pair-wise comparisons, as explained above, of
the number of cases with lost DNA and no CNA showed that losses
at 2p16.3 were significantly associated with asbestos exposure
(P¼0.03, Fisher’s exact test). Among the highly exposed patients
(X5 million fibres per gram) the 2p16.3 losses were even more
significantly associated with asbestos exposure (P¼0.02, Fisher’s
exact test). An example of the lost RP11-703K23 signals is shown in
Figure 2C. Gains and/or losses at 2p16 occurred in all histological
types of lung cancer. When the frequencies of losses, gains, and no
CNA were compared in different histological types, we found
losses at 2p16 in the exposed patients with any histological tumour
type, but the case numbers in each group were small and only SCC
showed significant P-values. CNA in SCC were significantly
associated with asbestos exposure at 2p16.2 (RP11-1114A19/
CEN2, P¼0.04, Fisher’s exact test) and with high-level exposure
at 2p16.3 (RP11-703K23/CEN2, P¼0.02, Fisher’s exact test).
In addition, the prevalence of probes that showed a CNA in each
case at 2p16 (probes RP11-703K23, RP11-347F1, and RP11-
1114A19) and at 2p21 (probes RP11-183P21 and RP11-963J22)
was calculated. At 2p16, the prevalence of at least one probe loss
was significantly increased in asbestos-exposed, particularly in
highly exposed, in comparison with non-exposed cases (Table 2b).
The difference was also significant between the exposed (100%, 2
out of 2 cases) and non-exposed (0%, 0 out of 7 cases) patients
with SCLC (P¼0.03, Fisher’s exact test). No significant association
was identified with asbestos when similar calculations were carried
out for the gains (data not shown). It can be assumed that among
the non-exposed of our study population no asbestos-induced
cancers exist, whereas among the exposed patients the proportion
of excess lung cancers because of asbestos exposure depends on
the risk level in the group, and may be roughly 50% (Karjalainen
et al, 1994). Thus, when combining the results of the three probes
at 2p16, the specificity of copy number losses at 2p16 in detecting
asbestos-related lung tumours would be 93%, but the sensitivity
Figure 2 (A) An example of a metaphase showing hybridisation signals
of the RP11-703K23 probe in chromosome 2. (B) Lung tumour cells
hybridised with the CEN2 centromeric probe (red) showing diploid to
tetraploid cells and with the RP11-963J22 probe (green) showing gain of
DNA at 2p21. (C) Lung tumour cells hybridised with the CEN2
centromeric probe (red) showing diploid to tetraploid cells and with the
RP11-703K23 probe (green) showing loss at 2p16.
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cancers in the exposed group are asbestos-related.
Allelic imbalance in 2p22.1–p16.1
A total of 27 lung tumours were microdissected for allele analyses
and their microsatellite allelotyping profiles were compared with
those in normal lung tissue of the same patients. Allelic imbalances
at 2p22.1–p16.1 in the lung tumours of the asbestos-exposed
and the non-exposed patients are shown in Table 3. The average
proportion of informative microsatellite markers was 67% (range
41–83%). This agrees well with the reported heterozygosity rate of
these markers. Microsatellite instability at 2p was observed in three
cases: in two ACs, one from an asbestos-exposed and one from a
non-exposed patient, and in one non-exposed SCLC. Although AI at
2p was observed to some extent in every lung tumour, we identified
more AI in the lung tumours of asbestos-exposed (on average 52%)
than in those of non-exposed patients (on average 32%). At 2p16.3
(D2S123), AI occurred in 63% of the asbestos-exposed and in 0%
of the non-exposed patients’ tumours (P¼0.08, Fisher’s exact test,
Table 3). As the markers, D2S2739 and D2S2251, adjacent to
D2S123 at 2p16 showed similar trends of asbestos association, we
also looked at the five markers at 2p16 together (Table 3, Figure 3).
Tumours having at least two informative markers out of five were
included in the analysis. Allelic imbalances at 2p16 were scored for
a tumour if at least two markers showed AI. We found significantly
more AI in asbestos-exposed patients compared with non-exposed
(P¼0.003, Fisher’s exact test; Figure 3).
DISCUSSION
We analysed 205 lung tumours for CNA at 2p and 27 lung tumours
for AI at the same region. We showed that copy number loss at
Table 2b Numbers (%) of lung tumours showing loss at 2p16 according to asbestos-exposure level and extent of the lost DNA
Number of probes
a showing loss at 2p16 Highly exp
b (n¼41) Exp
c (n¼29) Non-exp
d (n¼71)
0 32 (78) 24 (83) 65 (91)
1 5 (12) 3 (10) 4 (6)
2 4 (10) 1 (3.5) 2 (3)
3 0 (0) 1 (3.5) 0 (0)
Abbreviation: Exp¼exposed.
aIncluding the probes RP11-703K23, RP11-347F1, and RP11-1114A19.
bPulmonary fibre count X5 million fibres per gram.
cPulmonary fibre count
1–o5 million fibres per gram.
dPulmonary fibre count p0.5 million fibres per gram. P¼0.05, highly asbestos-exposed and asbestos-exposed vs non-exposed; P¼0.04, highly
asbestos-exposed vs non-exposed (P-values were calculated using w
2-test for the difference between at least one loss and no losses).
Table 2a The numbers (%) of highly asbestos-exposed (X5 million fibres), asbestos-exposed (1–o5 million) and non-exposed patients’ lung tumours
with lost (ratio o0.75), gained (ratio 41.3), or normal 2p DNA sequences
Probe
location RP11-183P21 RP11-963J22 RP11-703K23
a RP11-347F1 RP11-1114A19
2p21 2p21 2p16.3 2p16.3 2p16.2
n¼82 n¼75 n¼134 n¼95 n¼54
Highly
exp
(n¼31)
Exp
(n¼13)
Non-exp
(n¼38)
Highly
exp
(n¼22)
Exp
(n¼15)
Non-exp
(n¼38)
Highly
exp
(n¼41)
Exp
(n¼29)
Non-exp
(n¼64)
Highly
exp
(n¼27)
Exp
(n¼20)
Non-exp
(n¼48)
Highly
exp
(n¼18)
Exp
(n¼8)
Non-exp
(n¼28)
DNA status
Loss
b 2 (6) 0 (0) 1 (3) 0 (0) 0 (0) 1 (3) 6 (15) 2 (7) 1 (2) 5 (19) 3 (15) 4 (8) 2 (11) 3 (38) 3 (11)
Gain 9 (29) 4 (31) 14 (37) 14 (64) 5 (33) 17 (45) 2 (5) 4 (14) 6 (9) 2 (7) 3 (15) 8 (17) 2 (11) 1 (13) 1 (3)
Normal 20 (65) 9 (69) 23 (60) 8 (36) 10 (67) 20 (52) 33 (80) 23 (79) 57 (89) 20 (74) 14 (70) 36 (75) 14 (78) 4 (50) 24 (86)
Abbreviation: Exp¼exposed.
aThe probe providing best differentiation between the asbestos-exposed and non-exposed patients’ tumours. Fisher’s exact test between non-
exposed and exposed (X1 million, P¼0.09), and between non-exposed and highly asbestos-exposed (X5 million, P¼0.02).
bThe groups with the most significant difference
are given in bold.
Table 3 Allelic imbalance (AI) in 14 microsatellite markers at 2p22.1–p16.1 in lung tumours of asbestos-exposed and non-exposed patients
AI/n (%)
a
Microsatellite markers within the chromosomal region
2p22.1 2p21 2p16.3 2p16.2 2p16.1
Exposure
Asbestos fibre
count
b D2S2328 D2S2259 D2S119 D2S2298 D2S2174 D2S2240 D2S2378 D2S2182 D2S391 D2S2739 D2S123 D2S2251 D2S2153 D2S378
Asbestos-
exposed
n¼13
33.4 (5.9–145.0) 2/11 (18) 5/9 (56) 5/10 (50) 4/10 (40) 3/5 (60) 5/10 (50) 7/8 (88) 1/3 (33) 4/7 (57) 8/11 (73) 5/8 (63) 4/7 (57) 3/8 (38) 4/9 (44)
Non-
exposed
n¼14
0.06 (0.0–0.5) 1/8 (13) 3/7 (43) 1/8 (13) 3/9 (33) 3/7 (43) 4/10 (40) 4/10 (40) 3/6 (50) 3/7 (43) 3/9 (33) 0/5 (0) 2/9 (22) 3/8 (38) 1/10 (10)
P
c 1.00 1.00 0.15 1.00 1.00 1.00 0.07 1.00 1.00 0.17 0.08 0.30 1.00 0.14
aNumber of cases with AI/informative cases.
bMilliong
 1 dry lung; mean (range).
cP (Fisher’s exact test); bold if the corresponding marker is presented in Figure 3.
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asbestos exposure. Particularly, we found that the prevalence
of low copy number loss at 2p16 shown with three different
FISH probes was significantly associated with asbestos exposure
(P¼0.04, w
2-test). In addition, AI at 2p16 was detected more
frequently in the tumours of asbestos-exposed patients (P¼0.003,
Figure 3).
The chromosome count and structure in lung cancer cells often
show great variation. Some aberrations in chromosome 2 have
been detected in lung cancer, for example the amplification of the
MYCN locus (2p24) in SCLC (Knuutila, 2004; Kim et al, 2006).
Recently the fusion gene, EML4-ALK, resulting from an inversion
at 2p21/2p23, was found in 3–7% of non-small cell lung cancer
(NSCLC) (Soda et al, 2007; Koivunen et al, 2008). Furthermore, by
array comparative genomic hybridisation it has been shown that
52% of NSCLC carried gained sequences at 2p21.1–p14 indepen-
dent of histological type (Dehan et al, 2007). However, because the
asbestos exposure burden of a given lung cancer patient has not
usually been determined, the majority of earlier studies under-
standably lack association analyses between genomic findings and
asbestos exposure status. Our earlier array studies on lung cancer
showed that genomic alterations at 2p21–p16.3 may be related to
asbestos exposure in lung cancer patients (Nymark et al, 2006;
Wikman et al, 2007).
In this study, we have further characterised the asbestos-related
genetic aberrations at 2p in a large group of lung cancer patients.
We detected asbestos-associated loss and AI at 2p16 and localised
the core region at 2p16.3–p16.2 (Table 2a).
Our results indicate that asbestos specifically targets regions
such as on chromosome 2. Asbestos has been shown to cause
hyperdiploidy, loss of chromosomes, and chromosomal breakage
(Dopp and Schiffmann, 1998). Although the precise mechanisms
and outcomes of asbestos-induced DNA damage have not yet been
thoroughly established, the finding of DNA loss and AI at 2p16 in
the lung tumours of asbestos-exposed patients is in accordance
with the current knowledge on the behaviour of asbestos fibres.
Furthermore, common fragile sites may be prone to replicative
stress and increased frequency of AI. We have earlier detected an
association between fragile sites and some of the asbestos-
associated CNA (Nymark et al, 2006). The aphidicolin-sensitive
common fragile site, FRA2D, is located at 2p16.2 between the
markers, D2S123 and D2S2153, and seems to overlap with the
region showing asbestos-associated loss (Schwartz et al, 2006).
Some tumours, such as a cancer syndrome called the Carney
complex (CNC), have shown both amplifications and deletions
at 2p21-p16 (Matyakhina et al, 2003). The CNC syndrome is a
genetically heterogeneous disease associated with multiple neo-
plasms, such as skin, cardiac, and breast myxomas, as well as
endocrine tumours. The size of the CNA at 2p has been reported to
vary from case to case and from cell to cell, indicating that 2p is
indeed prone to variable alterations.
In our earlier work, the affected sequences in which the DNA
copy number differed significantly between lung tumours of
asbestos-exposed and non-exposed patients, was estimated to
situate at 2p21–p16.3 (Nymark et al, 2006). Here we were able to
more specifically localise the affected region to 2p16 (RP11-
703K23). Alternation of normal and abnormal loci makes it
challenging to identify typical asbestos-related alterations, parti-
cularly in a complex genome, such as in lung cancer, which often
shows polyploid genome (Mitelman et al, 2009). Nevertheless, by
Allelic imbalance (AI)c
2p16 Histologya
Asbestos 
fibre 
countb D2S2739 D2S123 D2S2251 D2S2153  D2S378  AI/n
SCLC  0  MSI  MSI            0/3 
SCC 0      0/3 
AC  0          0/5 
AC 0    0/3 
AC 0    1/2 
SCC 0      1/4 
AC 0    1/4 
AC 0        1/3 
SCC 0        0/3
SCC 0   1/2 
AC-SCC 0   2/2 
AC 0.1    1/3 
LCLC 0.48      0/2 
LCLC 0.5    1/2 
SCC 5.9   3/4 
SCC 5.99   2/2 
LCLC 8.4   3/3 
AC 9.39   4/5 
AC 10.8     2/4 
AC  12.6       MSI     MSI   1/2 
SCLC  12.8          0/5 
LCLC 19   3/3 
AC 35   2/3 
AC 72.9   1/2 
LCLC 90     2/4 
AC-SCC 145    0/4 
Figure 3 Significantly more allelic imbalances (AI) at 2p16 were found in asbestos-exposed patients’ lung tumours compared with those of non-exposed
(P¼0.003, Fisher’s exact test).
aAC, adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; LCLC, large cell lung carcinoma;
bmilliong
 1 dry lung;
cwhite, normal; light grey, no result; dark grey, allelic imbalance; MSI, microsatellite instability; bold when at least two markers
showed AI.
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scomparing locus-specific probes with a centromere probe to
obtain locus-specific CNA at 2p, we were able to identify asbestos-
associated CNA, although the alterations occurred at low level. We
anticipate that genomic alterations occurring at 2p may reflect
distinct events in lung tumours, some related to asbestos exposure
and some not. Independently of patients’ asbestos exposure status,
we detected frequent low copy number gains at 2p21, which
suggests that 2p21 may harbour genes important to the develop-
ment of lung cancer, such as the earlier mentioned oncogenic
EML4-ALK fusion gene. It seems that, although chromosome 2
may generally be affected by gains in lung tumours, asbestos may
cause breaks in the chromosome and thus result in additional
alterations, such as losses.
In conclusion, we show that locus-specific copy number loss
and AI at 2p16.3-p16.2 are associated with asbestos exposure in
lung tumours, whereas low-level copy number gains at 2p21 are
common in lung cancer in general. Probability based on
epidemiological studies has for a long time been used as a method
of indicating that asbestos exposure burden may be associated
with an individual’s lung cancer. We believe that the findings we
describe here may benefit the diagnosis of asbestos-associated lung
tumours, when combined with earlier identified asbestos-asso-
ciated alterations in other chromosomal regions, such as 19p13
and 9q33.1 (Ruosaari et al, 2008; Nymark et al, 2009).
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